MedWatch

Ambu CEO wants to avoid further downgrades: "I've communicated what I'm confident we can deliver this year"

Ambu’s new CEO, Britt Meelby Jensen, does not share her predecessor’s expectations for the Danish medtech firm, which is why she upturned his last guidance in one final downgrade to end them all.

Britt Meelby Jensen, newly appointed chief executive of Ambu, does not expect that there will be additional downgrade or layoff rounds at the medtech firm | Photo: Ambu/PR

When Britt Meelby Jensen examined Ambu’s sales figures after having assumed charge of the company, she did not recognize the optimistic expectation of growth of at least 13% that had been communicated to investors.

The projection was made by her predecessor, Juan Jose Gonzalez, who was fired some two months prior. Meelby Jensen was brought in to replace him by Ambu’s board of directors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs